Statistical analysis

PK Prathap Kanagala
JA Jayanth R. Arnold
AS Anvesha Singh
DC Daniel C. S. Chan
AC Adrian S. H. Cheng
JK Jamal N. Khan
GG Gaurav S. Gulsin
JY Jing Yang
LZ Lei Zhao
PG Pankaj Gupta
IS Iain B. Squire
LN Leong L. Ng
GM Gerry P. McCann
request Request a Protocol
ask Ask a question
Favorite

SPSS v22 was used for statistical analyses. Normality for continuous data was assessed using the Shapiro-Wilk test, histograms and Q-Q plots. Normally distributed data are expressed as mean ±SD. Non-parametric data are expressed as median (25–75% IQR). Categorical data are expressed as absolute numbers or percentages. For comparison of normally distributed data between the 3 groups, the one-way ANOVA with Bonferroni correction was used. For comparison of non-normally distributed data, the Kruskal-Wallis test was employed. The Chi-square or Mann-Whitney U tests were to compare categorical data, as appropriate. For additional between group comparisons, multiple linear regression was used to adjust for clinical variables, where the dependent variable was the log transformed plasma biomarker of interest and independent variables included age, gender, body mass index (BMI) and co-morbidities [diabetes, hypertension, lung disease, atrial fibrillation (AF), chronic kidney disease (CKD), CAD). Binary logistic regression was undertaken with the same adjustments to test for differences in the presence of elevated troponin-I levels between HF groups. Spearman’s rank correlations were performed to detect any important associations with NTpro-ANP. Kaplan-Meier analysis was undertaken to calculate event rates. The Log-Rank test was used to test differences in survival curves. CMR assessments of intra-observer and inter-observer variability were undertaken at least 4 weeks apart (by PK and JRA), on a subset of 10 randomly selected patients (S1 Table).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A